A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
NCT ID: NCT00071812
Last Updated: 2013-08-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
283 participants
INTERVENTIONAL
2003-12-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo plus SOC
Placebo
Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Belimumab 1 mg/kg plus SOC
Belimumab 1 mg/kg
Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Belimumab 4 mg/kg plus SOC
Belimumab 4 mg/kg
Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Belimumab 10 mg/kg plus SOC
Belimumab 10 mg/kg
Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belimumab 1 mg/kg
Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Belimumab 4 mg/kg
Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Belimumab 10 mg/kg
Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
Placebo
Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failed at least 1 disease modifying anti-rheumatic drug (DMARD) due to toxicity or lack of efficacy. These drugs must include 1 or more of the following: methotrexate, parenteral gold, sulfasalazine, leflunomide, and tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, etanercept or adalimumab)
* Active RA disease of at least moderate disease activity
* Be on a stable RA treatment regimen for at least the past 60 days (for DMARDS); if on non-steroidal anti-inflammatory drugs (NSAIDs) or steroids these must be at a stable dose for the last 30 days
Exclusion Criteria
* Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab) or interleukin-1 receptor antagonist (anakinra)
* Currently receiving or received within the last 6 months the following: anti-CD20 antibody (rituximab) or cyclophosphamide
* Steroid injection into any joint within the last 30 days
* History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency
* History of chronic infection that has been active within last 6 months, or herpes zoster within last 90 days, or any infection requiring hospitalization or intravenous medication within last 60 days
* Human immunodeficiency virus (HIV), Hepatitis-B, Hepatitis-C
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Human Genome Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Arthritis Research
Paradise Valley, Arizona, United States
University of Arizona
Tucson, Arizona, United States
Scripps Clinic
La Jolla, California, United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Wallace Rheumatic Disease Center
Los Angeles, California, United States
Stanford University School of Medicine
Palo Alto, California, United States
Boling Clinical Trials
Rancho Cucamonga, California, United States
UCDMC
Sacramento, California, United States
Arthritis Care Center, Inc.
San Jose, California, United States
Arthritis Associates & Osteoporosis Center Of Colorado Springs
Colorado Springs, Colorado, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States
Rheumatology Associates of Central Florida
Orlando, Florida, United States
Tampa Medical Group, P.A.
Tampa, Florida, United States
Radiant Research Boise
Boise, Idaho, United States
Institute of Arthritis and Research
Idaho Falls, Idaho, United States
Northwestern University Medical School
Chicago, Illinois, United States
Rheumatology Associates
Chicago, Illinois, United States
Rockford Clinic
Rockford, Illinois, United States
Medical Specialists
Munster, Indiana, United States
Kentuckiana Center for Better Bone and Joint Health
Louisville, Kentucky, United States
Ochsner Clinic Foundation
Baton Rouge, Louisiana, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
The Osteoporosis and Arthritis Clinical Trial Center
Cumberland, Maryland, United States
Center for Rhematology and Bone Research
Wheaton, Maryland, United States
Tufts - New England Medical Center
Boston, Massachusetts, United States
The University of Michigan Health System
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University in St. Louis
St Louis, Missouri, United States
Arthritis Center of Nebraska
Lincoln, Nebraska, United States
Arthritis and Osteoporosis Center
Concord, New Hampshire, United States
Strafford Medical Associates, P.A.
Dover, New Hampshire, United States
The Center For Rheumatology
Albany, New York, United States
SUNY-Downstate Medical Center
Brooklyn, New York, United States
North Shore University Hospital
Manhasset, New York, United States
Jacobi Medical Center
The Bronx, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Arthritis Clinic and Carolina Bone and Joint
Charlotte, North Carolina, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
Stat Research, Inc.
Dayton, Ohio, United States
McBride Clinic
Oklahoma City, Oklahoma, United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
Oklahoma Center For Arthritis Therapy & Research
Tulsa, Oklahoma, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
University of Pittsburgh School of Medicine & ASPH
Pittsburgh, Pennsylvania, United States
Rheumatic Disease Associates
Willow Grove, Pennsylvania, United States
Arthritis Centers of Texas
Dallas, Texas, United States
Research Associates of North Texas
Dallas, Texas, United States
UT Southwestern Medical Center at Dallas
Dallas, Texas, United States
Houston Institute for Clinical Research
Houston, Texas, United States
Texas Research Center
Sugar Land, Texas, United States
Arthritis and Rheumatic Diseases Clinic
Morgan, Utah, United States
Arthritis Clinic of Northern Virginia, P.C.
Arlington, Virginia, United States
Edmonds Rheumatology Associates
Edmonds, Washington, United States
Evergreen Clinical Reserach
Edmonds, Washington, United States
Arthritis Northwest Rheumatology
Spokane, Washington, United States
Rheumatology Northwest Clinical Trials
Yakima, Washington, United States
Rheumatic Disease Center
Glendale, Wisconsin, United States
Gundersen Clinic, Ltd.
La Crosse, Wisconsin, United States
The Medical College of Wisconsin , Inc
Milwaukee, Wisconsin, United States
Marshfield Medical Research Foundation
Wausau, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May;40(5):579-89. doi: 10.3899/jrheum.120886. Epub 2013 Apr 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LBRA01
Identifier Type: -
Identifier Source: org_study_id